SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024
Measures of financial toxicity in cancer survivors: a systematic review.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A systematic review of financial toxicity measurement instruments for cancer patients based on the COSMIN guideline.Journal of patient-reported outcomes · 2026Pooled it
- Financial toxicity among patients with lung cancer: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Measuring the Socioeconomic Impact of Cancer: A Systematic Review and Standardized Assessment of Patient-Reported Outcomes (PRO) Instruments.PharmacoEconomics - open · 2025Pooled it
- Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs).Journal of cancer survivorship : research and practice · 2026Article
- Toward a validated European instrument to measure the socioeconomic impact of cancer.International journal of cancer · 2026Article
- Financial Toxicity in Women with Endometriosis: Psychometric Validation of the Polish COST-FACIT with Analysis of Demographic and Clinical Factors.Healthcare (Basel, Switzerland) · 2026Article
- Long-term quality of life, financial toxicity, and decision regret following therapeutic and prophylactic gastrectomy for cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Beyond drug toxicity: the hidden burden of financial toxicity in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2026Article
- Financial Toxicity in Selected Head and Neck Cancers: A Scoping Review of Measurement, Burden, and Outcomes.Cancers · 2026Review
- Impacts of Financial Toxicity on Patients Receiving Dialysis: An Exploratory Qualitative Study.Kidney360 · 2026Article
- Ten Healthcare Delivery Trends and Their Measurement and Methodological Implications for Cancer Health Services Research.Health services research · 2026Article
- Access to cancer medicines in Kenya: a scoping review of costs, financial toxicity, quality of life and policy impacts.Ecancermedicalscience · 2026Review
- Detection of Financial Toxicity in Italian Uremic Patients: A Single Center Cross-Sectional Study.International journal of nephrology and renovascular disease · 2025Article
- Financial toxicity after trauma and acute care surgery: recommendations for measuring long-term financial hardship.Trauma surgery & acute care open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeComprehensive cancer-related financial toxicity (FT) measures as a multidimensional construct are lacking. The aims of this systematic review were to (1) identify full measures designed explicitly for assessing FT and evaluate their psychometric properties (content validity, structural validity, reliability, and other measurement properties) using Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN), and (2) provide an analysis of the domains of FT covered in these measures.
methodsMEDLINE, CINAHL, Web of Science, and Cochrane CENTRAL were searched for quantitative studies published from January 2000 to July 2023 that reported psychometric properties of FT measures in cancer survivors. The psychometric properties of FT measures and study risk of bias were analysed using COSMIN. Each FT measure was compared against the six domains of FT recommended by Witte and colleagues. Results were synthesized narratively. The detailed search strategies are available in Table S1.
resultsSix FT tools including the COST-FACIT, PROFFIT, FIT, SFDQ, HARDS, and ENRICh-Spanish were identified. The COST-FACIT measure had good measurement properties. No measure reached an excellent level for overall quality but was mostly rated as sufficient. The SFDQ, HARDS, and ENRICh-Spanish were the most comprehensive in the inclusion of the six domains of FT.
conclusionThis review emphasizes the need for validated multidimensional FT measures that can be applied across various cancer types, healthcare settings, and cultural backgrounds. Furthermore, a need to develop practical screening tools with high predictive ability for FT is highly important, considering the significant consequences of FT. Addressing these gaps in future research will further enhance the understanding of FT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.